{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:56:43Z","timestamp":1740149803403,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12328-021-01588-z","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T19:03:37Z","timestamp":1641323017000},"page":"668-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pseudoprogression of lung large cell neuroendocrine carcinoma resembling pancreatic cancer during durvalumab therapy"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7552-9908","authenticated-orcid":false,"given":"Aiji","family":"Hattori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namie","family":"Tachikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodai","family":"Fujibe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiaki","family":"Oiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Hataji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"1588_CR1","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Stephen Hodi F, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"1588_CR2","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti\u2013pd-l1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"1588_CR3","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1172\/JCI80012","volume":"125","author":"E Buchbinder","year":"2015","unstructured":"Buchbinder E, Stephen Hodi F. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Investig. 2015;125:3377\u201383.","journal-title":"J Clin Investig"},{"key":"1588_CR4","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541\u20133.","journal-title":"J Clin Oncol"},{"key":"1588_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jtho.2016.05.002","volume":"11","author":"K Ito","year":"2016","unstructured":"Ito K, Hataji O, Katsuta K, et al. \u201cPseudoprogression\u201d of pulmonary pleomorphic carcinoma during nivolumab therapy. J Thorac Oncol. 2016;11:117\u20139.","journal-title":"J Thorac Oncol"},{"key":"1588_CR6","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, Oday S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320.","journal-title":"Clin Cancer Res"},{"key":"1588_CR7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","volume":"16","author":"W Jia","year":"2019","unstructured":"Jia W, Gao Q, Han A, et al. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019;16:655\u201370.","journal-title":"Cancer Biol Med"},{"key":"1588_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002280","author":"B Pi","year":"2021","unstructured":"Pi B, Wang J, Tong Y, et al. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. Eur J Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1097\/MEG.0000000000002280.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1588_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10396-013-0483-y","volume":"40","author":"Terminology and Diagnostic Criteria Committee, Japan Society of Ultrasonics in Medicine","year":"2013","unstructured":"Terminology and Diagnostic Criteria Committee, Japan Society of Ultrasonics in Medicine. Ultrasonographic diagnostic criteria for pancreatic cancer. Med Ultrason. 2013;40:497\u2013504.","journal-title":"Med Ultrason"},{"key":"1588_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1148\/radiol.2441041978","volume":"244","author":"J Ahualli","year":"2007","unstructured":"Ahualli J. The double duct sign. Radiology. 2007;244:314\u20135.","journal-title":"Radiology"},{"key":"1588_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4103\/2303-9027.162993","volume":"4","author":"DG Adler","year":"2015","unstructured":"Adler DG, Diehl DL. Missed lesions in endoscopic ultrasound. Endosc Ultrasound. 2015;4:165\u20137.","journal-title":"Endosc Ultrasound."},{"key":"1588_CR12","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1158\/1078-0432.CCR-18-3206","volume":"25","author":"J-C Pignon","year":"2019","unstructured":"Pignon J-C, Jegede O, Shukla SA, et al. irRECIST for the evaluation of candidate biomarkers of response to nivolumab in metastatic clear cell renal cell carcinoma: analysis of a phase II prospective clinical trial. Clin Cancer Res. 2019;25:2174\u201384.","journal-title":"Clin Cancer Res"},{"key":"1588_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:143\u201352.","journal-title":"Lancet Oncol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01588-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01588-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01588-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T20:59:33Z","timestamp":1674334773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01588-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01588-z","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"3 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest and no financial arrangement with any company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights"}},{"value":"Informed consent was obtained from the patient for the publication of his information and imaging.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}